Venous thrombosis and prothrombotic factors in inflammatory bowel disease

World Journal of Gastroenterology

Volumn 20, Issue 17, 2014, Pages 4857-4872

  Magro, Fernando ^a,b,c   Soares, João Bruno ^d   Fernandes, Dália ^d,e  

^a Universidade do Porto   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

^c UNIVERSITY OF PORTO   (Portugal)

^d HOSPITAL DE BRAGA   (Portugal)

^e Centro Hospitalar da Cova da Beira   (Portugal)

Author keywords

Acquired; Genetic; Inflammatory bowel disease; Prothrombotic; Risk of venous thrombosis; Venous thrombosis

Indexed keywords

5, 10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ANTITHROMBIN; C REACTIVE PROTEIN; CD40 LIGAND; INTERLEUKIN 1BETA; INTERLEUKIN 6; NITRIC OXIDE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTHROMBIN; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; THROMBIN ANTITHROMBIN COMPLEX; THROMBOMODULIN; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR; ANTICOAGULANT AGENT; AUTACOID; BLOOD CLOTTING FACTOR;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; BIBLIOGRAPHIC DATABASE; BLOOD CLOTTING DISORDER; CLINICAL FEATURE; CROHN DISEASE; DISEASE ACTIVITY; DISEASE ASSOCIATION; HEMOSTASIS; HEREDITY; HOSPITALIZATION; HUMAN; INFLAMMATORY BOWEL DISEASE; INFORMATION PROCESSING; META ANALYSIS (TOPIC); MORBIDITY; PHENOTYPE; PREGNANCY; PREVALENCE; RECURRENT DISEASE; RISK FACTOR; SYSTEMATIC REVIEW (TOPIC); THROMBOPHILIA; ULCERATIVE COLITIS; VEIN THROMBOSIS; ANIMAL; BLOOD; BLOOD CLOTTING; COLITIS, ULCERATIVE; COMPLICATION; DRUG EFFECTS; GENETIC PREDISPOSITION; GENETICS; METABOLISM; VENOUS THROMBOSIS;

ANIMALS; ANTICOAGULANTS; BLOOD COAGULATION; BLOOD COAGULATION FACTORS; COLITIS, ULCERATIVE; CROHN DISEASE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFLAMMATION MEDIATORS; PHENOTYPE; RISK FACTORS; VENOUS THROMBOSIS;

EID: 84899817573     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i17.4857     Document Type: Article

References (148)

1. Bargen J, Barker NW. Extensive arterial and venous thrombosis complicating chronic ulcerative colitis. Arch Intern Med 1936; 58: 17-31 [DOI: 10.1001/archinte.1936.00170110025002]
2. Murthy SK, Nguyen GC. Venous thromboembolism in inflammatory bowel disease: an epidemiological review. Am J Gastroenterol 2011; 106: 713-718 [PMID: 21407182 DOI: 10.1038/ajg.2011.53]
3. Yuhara H, Steinmaus C, Corley D, Koike J, Igarashi M, Suzuki T, Mine T. Meta-analysis: the risk of venous thromboembolism in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2013; 37: 953-962 [PMID: 23550660 DOI: 10.1111/apt.12294]
4. Tan VP, Chung A, Yan BP, Gibson PR. Venous and arterial disease in inflammatory bowel disease. J Gastroenterol Hepatol 2013; 28: 1095-1113 [PMID: 23662785 DOI: 10.1111/jgh.12260]
5. Tichelaar YI, Kluin-Nelemans HJ, Meijer K. Infections and inflammatory diseases as risk factors for venous thrombosis. A systematic review. Thromb Haemost 2012; 107: 827-837 [PMID: 22437808 DOI: 10.1160/TH11-09-0611]
6. Grip O, Svensson PJ, Lindgren S. Inflammatory bowel disease promotes venous thrombosis earlier in life. Scand J Gastroenterol 2000; 35: 619-623 [PMID: 10912662]
7. Talbot RW, Heppell J, Dozois RR, Beart RW. Vascular complications of inflammatory bowel disease. Mayo Clin Proc 1986; 61: 140-145 [PMID: 3080643]
8. Bernstein CN, Blanchard JF, Houston DS, Wajda A. The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease: a population-based cohort study. Thromb Haemost 2001; 85: 430-434 [PMID: 11307809]
9. Miehsler W, Reinisch W, Valic E, Osterode W, Tillinger W, Feichtenschlager T, Grisar J, Machold K, Scholz S, Vogelsang H, Novacek G. Is inflammatory bowel disease an independent and disease specific risk factor for thromboembolism? Gut 2004; 53: 542-548 [PMID: 15016749]
10. Huerta C, Johansson S, Wallander MA, García Rodríguez LA. Risk factors and short-term mortality of venous thromboembolism diagnosed in the primary care setting in the United Kingdom. Arch Intern Med 2007; 167: 935-943 [PMID: 17502535 DOI: 10.1001/archinte.167.9.935]
11. Saleh T, Matta F, Yaekoub AY, Danescu S, Stein PD. Risk of venous thromboembolism with inflammatory bowel disease. Clin Appl Thromb Hemost 2011; 17: 254-258 [PMID: 20211927 DOI: 10.1177/1076029609360528]
12. Nguyen GC, Sam J. Rising prevalence of venous thromboembolism and its impact on mortality among hospitalized inflammatory bowel disease patients. Am J Gastroenterol 2008; 103: 2272-2280 [PMID: 18684186 DOI: 10.1111/j.1572-0241.2008.02052. x]
13. Kappelman MD, Horvath-Puho E, Sandler RS, Rubin DT, Ullman TA, Pedersen L, Baron JA, Sørensen HT. Thromboembolic risk among Danish children and adults with inflammatory bowel diseases: a population-based nationwide study. Gut 2011; 60: 937-943 [PMID: 21339206 DOI: 10.1136/ gut.2010.228585]
14. Nguyen GC, Boudreau H, Harris ML, Maxwell CV. Outcomes of obstetric hospitalizations among women with inflammatory bowel disease in the United States. Clin Gastroenterol Hepatol 2009; 7: 329-334 [PMID: 19027089 DOI: 10.1016/j.cgh.2008.10.022]
15. Bröms G, Granath F, Linder M, Stephansson O, Elmberg M, Kieler H. Complications from inflammatory bowel disease during pregnancy and delivery. Clin Gastroenterol Hepatol 2012; 10: 1246-1252 [PMID: 22922307 DOI: 10.1016/ j.cgh.2012.08.018]
16. Novacek G, Weltermann A, Sobala A, Tilg H, Petritsch W, Reinisch W, Mayer A, Haas T, Kaser A, Feichtenschlager T, Fuchssteiner H, Knoflach P, Vogelsang H, Miehsler W, Platzer R, Tillinger W, Jaritz B, Schmid A, Blaha B, Dejaco C, Eichinger S. Inflammatory bowel disease is a risk factor for recurrent venous thromboembolism. Gastroenterology 2010; 139: 779-787, 787. e1 [PMID: 20546736 DOI: 10.1053/j.gastro.2010.05.026]
17. Solem CA, Loftus EV, Tremaine WJ, Sandborn WJ. Venous thromboembolism in inflammatory bowel disease. Am J Gastroenterol 2004; 99: 97-101 [PMID: 14687149]
18. Jackson LM, O'Gorman PJ, O'Connell J, Cronin CC, Cotter KP, Shanahan F. Thrombosis in inflammatory bowel disease: clinical setting, procoagulant profile and factor V Leiden. QJM 1997; 90: 183-188 [PMID: 9093595]
19. Grainge MJ, West J, Card TR. Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study. Lancet 2010; 375: 657-663 [PMID: 20149425 DOI: 10.1016/S0140-6736(09)61963-2]
20. Bernstein CN, Nabalamba A. Hospitalization-based major comorbidity of inflammatory bowel disease in Canada. Can J Gastroenterol 2007; 21: 507-511 [PMID: 17703250]
21. Sridhar AR, Parasa S, Navaneethan U, Crowell MD, Olden K. Comprehensive study of cardiovascular morbidity in hospitalized inflammatory bowel disease patients. J Crohns Colitis 2011; 5: 287-294 [PMID: 21683298 DOI: 10.1016/j.crohns.2011.01.011]
22. Rothberg MB, Lindenauer PK, Lahti M, Pekow PS, Selker HP. Risk factor model to predict venous thromboembolism in hospitalized medical patients. J Hosp Med 2011; 6: 202-209 [PMID: 21480491 DOI: 10.1002/jhm.888]
23. Merrill A, Millham F. Increased risk of postoperative deep vein thrombosis and pulmonary embolism in patients with inflammatory bowel disease: a study of National Surgical Quality Improvement Program patients. Arch Surg 2012; 147: 120-124 [PMID: 22006853 DOI: 10.1001/archsurg.2011.297]
24. Wallaert JB, De Martino RR, Marsicovetere PS, Goodney PP, Finlayson SR, Murray JJ, Holubar SD. Venous thromboembolism after surgery for inflammatory bowel disease: are there modifiable risk factors? Data from ACS NSQIP. Dis Colon Rectum 2012; 55: 1138-1144 [PMID: 23044674 DOI: 10.1097/DCR.0b013e3182698f60]
25. Papay P, Miehsler W, Tilg H, Petritsch W, Reinisch W, Mayer A, Haas T, Kaser A, Feichtenschlager T, Fuchssteiner H, Knoflach P, Vogelsang H, Platzer R, Tillinger W, Jaritz B, Schmid A, Blaha B, Dejaco C, Sobala A, Weltermann A, Eichinger S, Novacek G. Clinical presentation of venous thromboembolism in inflammatory bowel disease. J Crohns Colitis 2013; 7: 723-729 [PMID: 23127785 DOI: 10.1016/j.crohns.2012.10.008]
26. Zöller B, Li X, Sundquist J, Sundquist K. Autoimmune diseases and venous thromboembolism: a review of the literature. Am J Cardiovasc Dis 2012; 2: 171-183 [PMID: 22937487]
27. Esmon CT. The interactions between inflammation and coagulation. Br J Haematol 2005; 131: 417-430 [PMID: 16281932 DOI: 10.1111/j.1365-2141.2005.05753.x]
28. Zöller B, Li X, Sundquist J, Sundquist K. Risk of pulmonary embolism in patients with autoimmune disorders: a nationwide follow-up study from Sweden. Lancet 2012; 379: 244-249 [PMID: 22119579 DOI: 10.1016/S0140-6736(11)61306-8]
29. Lindmark E, Tenno T, Siegbahn A. Role of platelet P-selectin and CD40 ligand in the induction of monocytic tissue factor expression. Arterioscler Thromb Vasc Biol 2000; 20: 2322-2328 [PMID: 11031222]
30. Parry GC, Mackman N. NF-κB Mediated Transcription in Human Monocytic Cells and Endothelial Cells. Trends Car-diovasc Med 1998; 8: 138-142 [PMID: 21235924 DOI: 10.1016/ S1050-1738(98)00002-4]
31. Cermak J, Key NS, Bach RR, Balla J, Jacob HS, Vercellotti GM. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood 1993; 82: 513-520 [PMID: 8329706]
32. Stouthard JM, Levi M, Hack CE, Veenhof CH, Romijn HA, Sauerwein HP, van der Poll T. Interleukin-6 stimulates coagulation, not fibrinolysis, in humans. Thromb Haemost 1996; 76: 738-742 [PMID: 8950783]
33. van der Poll T, Büller HR, ten Cate H, Wortel CH, Bauer KA, van Deventer SJ, Hack CE, Sauerwein HP, Rosenberg RD, ten Cate JW. Activation of coagulation after administration of tumor necrosis factor to normal subjects. N Engl J Med 1990; 322: 1622-1627 [PMID: 2188129 DOI: 10.1056/ NEJM199006073222302]
34. Fukudome K, Esmon CT. Identification, cloning, and regulation of a novel endothelial cell protein C/activated protein C receptor. J Biol Chem 1994; 269: 26486-26491 [PMID: 7929370]
35. Klein NJ, Shennan GI, Heyderman RS, Levin M. Alteration in glycosaminoglycan metabolism and surface charge on human umbilical vein endothelial cells induced by cytokines, endotoxin and neutrophils. J Cell Sci 1992; 102 (Pt 4): 821-832 [PMID: 1429895]
36. Chen Y, Wang J, Yao Y, Yuan W, Kong M, Lin Y, Geng D, Nie R. CRP regulates the expression and activity of tissue factor as well as tissue factor pathway inhibitor via NF-kappaB and ERK 1/2 MAPK pathway. FEBS Lett 2009; 583: 2811-2818 [PMID: 19631649 DOI: 10.1016/j.febslet.2009.07.037]
37. Chen C, Nan B, Lin P, Yao Q. C-reactive protein increases plasminogen activator inhibitor-1 expression in human endothelial cells. Thromb Res 2008; 122: 125-133 [PMID: 17949793 DOI: 10.1016/j.thromres.2007.09.006]
38. Singh U, Devaraj S, Jialal I. C-reactive protein decreases tissue plasminogen activator activity in human aortic endothelial cells: evidence that C-reactive protein is a procoagulant. Arterioscler Thromb Vasc Biol 2005; 25: 2216-2221 [PMID: 16123325 DOI: 10.1161/01.ATV.0000183718.62409.ea]
39. Burstein SA. Cytokines, platelet production and hemostasis. Platelets 1997; 8: 93-104 [PMID: 20297930 DOI: 10.1080/09537 109709169324]
40. Bhagat K, Vallance P. Inflammatory cytokines impair endothelium-dependent dilatation in human veins in vivo. Circulation 1997; 96: 3042-3047 [PMID: 9386173]
41. Bisoendial RJ, Kastelein JJ, Levels JH, Zwaginga JJ, van den Bogaard B, Reitsma PH, Meijers JC, Hartman D, Levi M, Stroes ES. Activation of inflammation and coagulation after infusion of C-reactive protein in humans. Circ Res 2005; 96: 714-716 [PMID: 15774855 DOI: 10.1161/01.RES.0000163015.67711.AB]
42. Hein TW, Singh U, Vasquez-Vivar J, Devaraj S, Kuo L, Jialal I. Human C-reactive protein induces endothelial dysfunction and uncoupling of eNOS in vivo. Atherosclerosis 2009; 206: 61-68 [PMID: 19268941 DOI: 10.1016/j.atherosclerosis.2009.0 2.002]
43. Danese S, Papa A, Saibeni S, Repici A, Malesci A, Vecchi M. Inflammation and coagulation in inflammatory bowel disease: The clot thickens. Am J Gastroenterol 2007; 102: 174-186 [PMID: 17100967 DOI: 10.1111/j.1572-0241.2006.00943.x]
44. Scaldaferri F, Lancellotti S, Pizzoferrato M, De Cristofaro R. Haemostatic system in inflammatory bowel diseases: new players in gut inflammation. World J Gastroenterol 2011; 17: 594-608 [PMID: 21350708 DOI: 10.3748/wjg.v17.i5.594]
45. Zitomersky NL, Verhave M, Trenor CC. Thrombosis and inflammatory bowel disease: a call for improved awareness and prevention. Inflamm Bowel Dis 2011; 17: 458-470 [PMID: 20848518 DOI: 10.1002/ibd.21334]
46. Yoshida H, Russell J, Senchenkova EY, Almeida Paula LD, Granger DN. Interleukin-1beta mediates the extra-intestinal thrombosis associated with experimental colitis. Am J Pathol 2010; 177: 2774-2781 [PMID: 20971730 DOI: 10.2353/ajpath. 2010.100205]
47. Yoshida H, Yilmaz CE, Granger DN. Role of tumor necrosis factor-α in the extraintestinal thrombosis associated with colonic inflammation. Inflamm Bowel Dis 2011; 17: 2217-2223 [PMID: 21987296 DOI: 10.1002/ibd.21593]
48. Larsen TB, Nielsen JN, Fredholm L, Lund ED, Brandslund I, Munkholm P, Hey H. Platelets and anticoagulant capacity in patients with inflammatory bowel disease. Pathophysiol Haemost Thromb 2002; 32: 92-96 [PMID: 12214155]
49. Chamouard P, Desprez D, Hugel B, Kunzelmann C, Gidon-Jeangirard C, Lessard M, Baumann R, Freyssinet JM, Grunebaum L. Circulating cell-derived microparticles in Crohn's disease. Dig Dis Sci 2005; 50: 574-580 [PMID: 15810645]
50. Palkovits J, Novacek G, Kollars M, Hron G, Osterode W, Quehenberger P, Kyrle PA, Vogelsang H, Reinisch W, Papay P, Weltermann A. Tissue factor exposing microparticles in inflammatory bowel disease. J Crohns Colitis 2013; 7: 222-229 [PMID: 22705067 DOI: 10.1016/j.crohns.2012.05.016]
51. Hudson M, Chitolie A, Hutton RA, Smith MS, Pounder RE, Wakefield AJ. Thrombotic vascular risk factors in inflammatory bowel disease. Gut 1996; 38: 733-737 [PMID: 8707120]
52. Kume K, Yamasaki M, Tashiro M, Yoshikawa I, Otsuki M. Activations of coagulation and fibrinolysis secondary to bowel inflammation in patients with ulcerative colitis. Intern Med 2007; 46: 1323-1329 [PMID: 17827828]
53. Zezos P, Papaioannou G, Nikolaidis N, Vasiliadis T, Giouleme O, Evgenidis N. Elevated plasma von Willebrand factor levels in patients with active ulcerative colitis reflect endothelial perturbation due to systemic inflammation. World J Gastroenterol 2005; 11: 7639-7645 [PMID: 16437691]
54. Smith CJ, Haire WD, Kaufman SS, Mack DR. Determination of prothrombin activation fragments in young patients with inflammatory bowel disease. Am J Gastroenterol 1996; 91: 1221-1225 [PMID: 8651175]
55. Chamouard P, Grunebaum L, Wiesel ML, Frey PL, Wittersheim C, Sapin R, Baumann R, Cazenave JP. Prothrombin fragment 1 + 2 and thrombin-antithrombin III complex as markers of activation of blood coagulation in inflammatory bowel diseases. Eur J Gastroenterol Hepatol 1995; 7: 1183-1188 [PMID: 8789309]
56. Lake AM, Stauffer JQ, Stuart MJ. Hemostatic alterations in inflammatory bowel disease: response to therapy. Am J Dig Dis 1978; 23: 897-902 [PMID: 717349]
57. Chiarantini E, Valanzano R, Liotta AA, Cellai AP, Fedi S, Ilari I, Prisco D, Tonelli F, Abbate R. Hemostatic abnormalities in inflammatory bowel disease. Thromb Res 1996; 82: 137-146 [PMID: 9163067]
58. Souto JC, Martínez E, Roca M, Mateo J, Pujol J, González D, Fontcuberta J. Prothrombotic state and signs of endothelial lesion in plasma of patients with inflammatory bowel disease. Dig Dis Sci 1995; 40: 1883-1889 [PMID: 7555437]
59. Saibeni S, Vecchi M, Valsecchi C, Faioni EM, Razzari C, de Franchis R. Reduced free protein S levels in patients with inflammatory bowel disease: prevalence, clinical relevance, and role of anti-protein S antibodies. Dig Dis Sci 2001; 46: 637-643 [PMID: 11318545]
60. Jorens PG, Hermans CR, Haber I, Kockx MM, Vermylen J, Parizel GA. Acquired protein C and S deficiency, inflammatory bowel disease and cerebral arterial thrombosis. Blut 1990; 61: 307-310 [PMID: 2148695]
61. Koutroubakis IE, Sfiridaki A, Mouzas IA, Maladaki A, Kapsoritakis A, Roussomoustakaki M, Kouroumalis EA, Manousos ON. Resistance to activated protein C and low levels of free protein S in Greek patients with inflammatory bowel disease. Am J Gastroenterol 2000; 95: 190-194 [PMID: 10638581 DOI: 10.1111/j.1572-0241.2000.01683.x]
62. Faioni EM, Ferrero S, Fontana G, Gianelli U, Ciulla MM, Vecchi M, Saibeni S, Biguzzi E, Cordani N, Franchi F, Bosari S, Cattaneo M. Expression of endothelial protein C receptor and thrombomodulin in the intestinal tissue of patients with inflammatory bowel disease. Crit Care Med 2004; 32: S266-S270 [PMID: 15118529]
63. Bernhard H, Deutschmann A, Leschnik B, Novak M, Hauer A, Haidl H, Rosenkranz A, Muntean W. Calibrated automated thrombin generation in paediatric patients with inflammatory bowel disease. Hamostaseologie 2009; 29 Suppl 1: S90-S93 [PMID: 19763358]
64. Bernhard H, Deutschmann A, Leschnik B, Schweintzger S, Novak M, Hauer A, Muntean W. Thrombin generation in pediatric patients with Crohn's disease. Inflamm Bowel Dis 2011; 17: 2333-2339 [PMID: 21287673 DOI: 10.1002/ibd.21631]
65. Chamouard P, Grunebaum L, Wiesel ML, Sibilia J, Coumaros G, Wittersheim C, Baumann R, Cazenave JP. Significance of diminished factor XIII in Crohn's disease. Am J Gastroenterol 1998; 93: 610-614 [PMID: 9576457 DOI: 10.1111/j.1572-0241.1998.174_b.x]
66. de Jong E, Porte RJ, Knot EA, Verheijen JH, Dees J. Disturbed fibrinolysis in patients with inflammatory bowel disease. A study in blood plasma, colon mucosa, and faeces. Gut 1989; 30: 188-194 [PMID: 2495239]
67. Gris JC, Schved JF, Raffanel C, Dubois A, Aguilar-Martinez P, Arnaud A, Sanchez N, Sarlat C, Balmès JL. Impaired fibrinolytic capacity in patients with inflammatory bowel disease. Thromb Haemost 1990; 63: 472-475 [PMID: 2119529]
68. Saibeni S, Bottasso B, Spina L, Bajetta M, Danese S, Gasbarrini A, de Franchis R, Vecchi M. Assessment of thrombin-activatable fibrinolysis inhibitor (TAFI) plasma levels in inflammatory bowel diseases. Am J Gastroenterol 2004; 99: 1966-1970 [PMID: 15447757 DOI: 10.1111/j.1572-0241.2004.30203.x]
69. Irving PM, Macey MG, Shah U, Webb L, Langmead L, Rampton DS. Formation of platelet-leukocyte aggregates in inflammatory bowel disease. Inflamm Bowel Dis 2004; 10: 361-372 [PMID: 15475744]
70. Collins CE, Rampton DS, Rogers J, Williams NS. Platelet aggregation and neutrophil sequestration in the mesenteric circulation in inflammatory bowel disease. Eur J Gastroenterol Hepatol 1997; 9: 1213-1217 [PMID: 9471028]
71. Webberley MJ, Hart MT, Melikian V. Thromboembolism in inflammatory bowel disease: role of platelets. Gut 1993; 34: 247-251 [PMID: 8432482]
72. Danese S, Katz JA, Saibeni S, Papa A, Gasbarrini A, Vecchi M, Fiocchi C. Activated platelets are the source of elevated levels of soluble CD40 ligand in the circulation of inflammatory bowel disease patients. Gut 2003; 52: 1435-1441 [PMID: 12970136]
73. Menchén L, Marín-Jiménez I, Arias-Salgado EG, Fontela T, Hernández-Sampelayo P, Rodríguez MC, Butta NV. Matrix metalloproteinase 9 is involved in Crohn's disease-associated platelet hyperactivation through the release of soluble CD40 ligand. Gut 2009; 58: 920-928 [PMID: 19039088 DOI: 10.1136/ gut.2008.150318]
74. Sawada-Hase N, Kiyohara T, Miyagawa J, Ueyama H, Nishibayashi H, Murayama Y, Kashihara T, Nakahara M, Miyazaki Y, Kanayama S, Nezu R, Shinomura Y, Matsuzawa Y. An increased number of CD40-high monocytes in patients with Crohn's disease. Am J Gastroenterol 2000; 95: 1516-1523 [PMID: 10894589 DOI: 10.1111/j.1572-0241.2000.01938.x]
75. Yan SL, Russell J, Harris NR, Senchenkova EY, Yildirim A, Granger DN. Platelet abnormalities during colonic inflammation. Inflamm Bowel Dis 2013; 19: 1245-1253 [PMID: 23518812 DOI: 10.1097/MIB.0b013e318281f3df]
76. Danese S, Sans M, Scaldaferri F, Sgambato A, Rutella S, Cittadini A, Piqué JM, Panes J, Katz JA, Gasbarrini A, Fiocchi C. TNF-alpha blockade down-regulates the CD40/CD40L pathway in the mucosal microcirculation: a novel antiinflammatory mechanism of infliximab in Crohn's disease. J Immunol 2006; 176: 2617-2624 [PMID: 16456024]
77. Papa A, Scaldaferri F, Danese S, Guglielmo S, Roberto I, Bonizzi M, Mocci G, Felice C, Ricci C, Andrisani G, Fedeli G, Gasbarrini G, Gasbarrini A. Vascular involvement in inflammatory bowel disease: pathogenesis and clinical aspects. Dig Dis 2008; 26: 149-155 [PMID: 18431065 DOI: 10.1159/000116773]
78. Hatoum OA, Binion DG, Otterson MF, Gutterman DD. Acquired microvascular dysfunction in inflammatory bowel disease: Loss of nitric oxide-mediated vasodilation. Gastroenterology 2003; 125: 58-69 [PMID: 12851871]
79. Rafiee P, Johnson CP, Li MS, Ogawa H, Heidemann J, Fisher PJ, Lamirand TH, Otterson MF, Wilson KT, Binion DG. Cyclosporine A enhances leukocyte binding by human intestinal microvascular endothelial cells through inhibition of p38 MAPK and iNOS. Paradoxical proinflammatory effect on the microvascular endothelium. J Biol Chem 2002; 277: 35605-35615 [PMID: 12110686 DOI: 10.1074/jbc.M205826200]
80. Horowitz S, Binion DG, Nelson VM, Kanaa Y, Javadi P, Lazarova Z, Andrekopoulos C, Kalyanaraman B, Otterson MF, Rafiee P. Increased arginase activity and endothelial dysfunction in human inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol 2007; 292: G1323-G1336 [PMID: 17218473 DOI: 10.1152/ajpgi.00499.2006]
81. Lancellotti S, De Filippis V, Pozzi N, Peyvandi F, Palla R, Rocca B, Rutella S, Pitocco D, Mannucci PM, De Cristofaro R. Formation of methionine sulfoxide by peroxynitrite at position 1606 of von Willebrand factor inhibits its cleavage by ADAMTS-13: A new prothrombotic mechanism in diseases associated with oxidative stress. Free Radic Biol Med 2010; 48: 446-456 [PMID: 19969076 DOI: 10.1016/j.freeradbiomed.2009. 11.020]
82. Stevens TR, James JP, Simmonds NJ, McCarthy DA, Laurenson IF, Maddison PJ, Rampton DS. Circulating von Willebrand factor in inflammatory bowel disease. Gut 1992; 33: 502-506 [PMID: 1582595]
83. Koutroubakis IE. Role of thrombotic vascular risk factors in inflammatory bowel disease. Dig Dis 2000; 18: 161-167 [PMID: 11279334]
84. Koutroubakis IE, Petinaki E, Anagnostopoulou E, Kritikos H, Mouzas IA, Kouroumalis EA, Manousos ON. Anticardiolipin and anti-beta2-glycoprotein I antibodies in patients with inflammatory bowel disease. Dig Dis Sci 1998; 43: 2507-2512 [PMID: 9824143]
85. Hudson M, Hutton RA, Wakefield AJ, Sawyerr AM, Pounder RE. Evidence for activation of coagulation in Crohn' s disease. Blood Coagul Fibrinolysis 1992; 3: 773-778 [PMID: 1489898]
86. Heneghan MA, Cleary B, Murray M, O'Gorman TA, McCarthy CF. Activated protein C resistance, thrombophilia, and inflammatory bowel disease. Dig Dis Sci 1998; 43: 1356-1361 [PMID: 9635631]
87. Nosbaum A, Goujon C, Fleury B, Guillot I, Nicolas JF, Bérard F. Arterial thrombosis with anti-phospholipid antibodies induced by infliximab. Eur J Dermatol 1998; 17: 546-547 [PMID: 17951145 DOI: 10.1684/ejd.2007.0280]
88. Vereckei E, Kriván G, Réti M, Szodoray P, Poór G, Kiss E. Anti-TNF-alpha-induced anti-phospholipid syndrome manifested as necrotizing vasculitis. Scand J Rheumatol 2010; 39: 175-177 [PMID: 20337548 DOI: 10.3109/03009740902832753]
89. Kang SS, Wong PW, Susmano A, Sora J, Norusis M, Ruggie N. Thermolabile methylenetetrahydrofolate reductase: an inherited risk factor for coronary artery disease. Am J Hum Genet 1991; 48: 536-545 [PMID: 1998339]
90. McCully KS. Homocysteine and vascular disease. Nat Med 1996; 2: 386-389 [PMID: 8597939]
91. Klerk M, Verhoef P, Clarke R, Blom HJ, Kok FJ, Schouten EG. MTHFR 677C--& gt; T polymorphism and risk of coronary heart disease: a meta-analysis. JAMA 2002; 288: 2023-2031 [PMID: 12387655]
92. Humphrey LL, Fu R, Rogers K, Freeman M, Helfand M. Homocysteine level and coronary heart disease incidence: a systematic review and meta-analysis. Mayo Clin Proc 2008; 83: 1203-1212 [PMID: 18990318 DOI: 10.4065/83.11.1203]
93. Ray JG. Meta-analysis of hyperhomocysteinemia as a risk factor for venous thromboembolic disease. Arch Intern Med 1998; 158: 2101-2106 [PMID: 9801176]
94. den Heijer M, Rosendaal FR, Blom HJ, Gerrits WB, Bos GM. Hyperhomocysteinemia and venous thrombosis: a metaanalysis. Thromb Haemost 1998; 80: 874-877 [PMID: 9869152]
95. Martí-Carvajal AJ, Solà I, Lathyris D, Karakitsiou DE, Simancas-Racines D. Homocysteine-lowering interventions for preventing cardiovascular events. Cochrane Database Syst Rev 2013; 1: CD006612 [PMID: 23440809 DOI: 10.1002/14651858. CD006612.pub3]
96. den Heijer M, Willems HP, Blom HJ, Gerrits WB, Cattaneo M, Eichinger S, Rosendaal FR, Bos GM. Homocysteine lowering by B vitamins and the secondary prevention of deep vein thrombosis and pulmonary embolism: A randomized, placebo-controlled, double-blind trial. Blood 2007; 109: 139-144 [PMID: 16960155 DOI: 10.1182/blood-2006-04-014654]
97. Cattaneo M, Vecchi M, Zighetti ML, Saibeni S, Martinelli I, Omodei P, Mannucci PM, de Franchis R. High prevalence of hyperchomocysteinemia in patients with inflammatory bowel disease: a pathogenic link with thromboembolic complications? Thromb Haemost 1998; 80: 542-545 [PMID: 9798965]
98. Oldenburg B, Van Tuyl BA, van der Griend R, Fijnheer R, van Berge Henegouwen GP. Risk factors for thromboembolic complications in inflammatory bowel disease: the role of hyperhomocysteinaemia. Dig Dis Sci 2005; 50: 235-240 [PMID: 15745078]
99. Oussalah A, Guéant JL, Peyrin-Biroulet L. Meta-analysis: hyperhomocysteinaemia in inflammatory bowel diseases. Aliment Pharmacol Ther 2011; 34: 1173-1184 [PMID: 21967576 DOI: 10.1111/j.1365-2036.2011.04864.x]
100. Tsiolakidou G, Koutroubakis IE. Thrombosis and inflammatory bowel disease-the role of genetic risk factors. World J Gastroenterol 2008; 14: 4440-4444 [PMID: 18680221]
101. Liebman HA, Kashani N, Sutherland D, McGehee W, Kam AL. The factor V Leiden mutation increases the risk of venous thrombosis in patients with inflammatory bowel disease. Gastroenterology 1998; 115: 830-834 [PMID: 9753484]
102. Guédon C, Le Cam-Duchez V, Lalaude O, Ménard JF, Lerebours E, Borg JY. Prothrombotic inherited abnormalities other than factor V Leiden mutation do not play a role in venous thrombosis in inflammatory bowel disease. Am J Gastroenterol 2001; 96: 1448-1454 [PMID: 11374681 DOI: 10.1111/j.1572-0241.2001.03797.x]
103. Turri D, Rosselli M, Simioni P, Tormene D, Grimaudo S, Martorana G, Siragusa S, Mariani G, Cottone M. Factor V Leiden and prothrombin gene mutation in inflammatory bowel disease in a Mediterranean area. Dig Liver Dis 2001; 33: 559-562 [PMID: 11816544]
104. Koutroubakis IE, Sfiridaki A, Tsiolakidou G, Theodoropoulou A, Livadiotaki A, Paspatis G, Kouroumalis EA. Genetic risk factors in patients with inflammatory bowel disease and vascular complications: case-control study. Inflamm Bowel Dis 2007; 13: 410-415 [PMID: 17206678 DOI: 10.1002/ibd.20076]
105. Spina L, Saibeni S, Battaglioli T, Peyvandi F, de Franchis R, Vecchi M. Thrombosis in inflammatory bowel diseases: role of inherited thrombophilia. Am J Gastroenterol 2005; 100: 2036-2041 [PMID: 16128949 DOI: 10.1111/ j.1572-0241.2005.42029.x]
106. Mózsik G, Nagy Z, Nagy A, Rumi G, Karádi O, Czimmer J, Matus Z, Tóth G, Pár A. Leiden mutation (as genetic) and environmental (retinoids) sequences in the acute and chronic inflammatory and premalignant colon disease in human gastrointestinal tract. J Physiol Paris 2001; 95: 489-494 [PMID: 11595480]
107. Over HH, Ulgen S, Tuǧlular T, Tezel A, Avşar E, Geyik G, Başgül S, Sayhan N, Ulusoy N, Kalayci C, Tözün N. Thrombophilia and inflammatory bowel disease: does factor V mutation have a role? Eur J Gastroenterol Hepatol 1998; 10: 827-829 [PMID: 9831402]
108. Nagy Z, Nagy A, Karádi O, Figler M, Rumi G, Süto G, Vincze A, Pár A, Mózsik G. Prevalence of the factor V Leiden mutation in human inflammatory bowel disease with different activity. J Physiol Paris 2001; 95: 483-487 [PMID: 11595479]
109. Bernstein CN, Sargent M, Vos HL, Rosendaal FR. Mutations in clotting factors and inflammatory bowel disease. Am J Gastroenterol 2007; 102: 338-343 [PMID: 17156138 DOI: 10.1111/j.1572-0241.2006.00974.x]
110. Vecchi M, Sacchi E, Saibeni S, Meucci G, Tagliabue L, Duca F, De Franchis R. Inflammatory bowel diseases are not associated with major hereditary conditions predisposing to thrombosis. Dig Dis Sci 2000; 45: 1465-1469 [PMID: 10961731]
111. Heliö T, Wartiovaara U, Halme L, Turunen UM, Mikkola H, Palotie A, Färkkilä M, Kontula K. Arg506Gln factor V mutation and Val34Leu factor XIII polymorphism in Finnish patients with inflammatory bowel disease. Scand J Gastroenterol 1999; 34: 170-174 [PMID: 10192195]
112. Haslam N, Standen GR, Probert CS. An investigation of the association of the factor V Leiden mutation and inflammatory bowel disease. Eur J Gastroenterol Hepatol 1999; 11: 1289-1291 [PMID: 10563542]
113. Papa A, De Stefano V, Gasbarrini A, Chiusolo P, Cianci R, Casorelli I, Paciaroni K, Cammarota G, Leone G, Gasbarrini G. Prevalence of factor V Leiden and the G20210A prothrombin-gene mutation in inflammatory bowel disease. Blood Coagul Fibrinolysis 2000; 11: 499-503 [PMID: 10937811]
114. Maher MM, Soloma SH. Assessment of thrombophilic abnormalities during the active state of inflammatory bowel disease. Saudi J Gastroenterol 2008; 14: 192-197 [PMID: 19568537 DOI: 10.4103/1319-3767.41743]
115. Yasa MH, Bolaman Z, Yukselen V, Kadikoylu G, Karaoglul AO, Batun S. Factor V Leiden G1691A, prothrombin G20210A, and MTHFR C677T mutations in Turkish inflammatory bowel disease patients. Hepatogastroenterology 2007; 54: 1438-1442 [PMID: 17708272]
116. Yilmaz S, Bayan K, Tüzün Y, Batun S, Altintaş A. A comprehensive analysis of 12 thrombophilic mutations and related parameters in patients with inflammatory bowel disease: data from Turkey. J Thromb Thrombolysis 2006; 22: 205-212 [PMID: 17111197 DOI: 10.1007/s11239-006-9032-5]
117. Mahmood A, Needham J, Prosser J, Mainwaring J, Trebble T, Mahy G, Ramage J. Prevalence of hyperhomocysteinaemia, activated protein C resistance and prothrombin gene mutation in inflammatory bowel disease. Eur J Gastroenterol Hepatol 2005; 17: 739-744 [PMID: 15947551]
118. Törüner M, Erkan O, Soykan I, Bozdayi M, Cetinkaya H, Yurdaydin C, Uzunalimoǧlu O, Ozden A. Factor V Leiden, prothrombin G20210A and MTHFR gene mutations in inflammatory bowel disease. Turk J Gastroenterol 2004; 15: 250-252 [PMID: 16249980]
119. Magro F, Dinis-Ribeiro M, Araújo FM, Pereira P, Fraga MC, Cunha-Ribeiro LM, Tomé-Ribeiro A. High prevalence of combined thrombophilic abnormalities in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 2003; 15: 1157-1163 [PMID: 14560147 DOI: 10.1097/01.meg.0000085474.12407.ce]
120. Bjerregaard LT, Nederby NJ, Fredholm L, Brandslund I, Munkholm P, Hey H. Hyperhomocysteinaemia, coagulation pathway activation and thrombophilia in patients with inflammatory bowel disease. Scand J Gastroenterol 2002; 37: 62-67 [PMID: 11843038]
121. Saibeni S, Vecchi M, Faioni EM, Franchi F, Rondonotti E, Borsi G, de Franchis R. Val34Leu factor XIII polymorphism in Italian patients with inflammatory bowel disease. Dig Liver Dis 2003; 35: 32-36 [PMID: 12725605]
122. Dahlbäck B. Advances in understanding pathogenic mechanisms of thrombophilic disorders. Blood 2008; 112: 19-27 [PMID: 18574041 DOI: 10.1182/blood-2008-01-077909]
123. Zhong M, Dong XW, Zheng Q, Tong JL, Ran ZH. Factor V Leiden and thrombosis in patients with inflammatory bowel disease (IBD): a meta-analysis. Thromb Res 2011; 128: 403-409 [PMID: 21831411 DOI: 10.1016/j.thromres.2011.07.014]
124. Liang J, Wu S, Feng B, Lei S, Luo G, Wang J, Li K, Li X, Xie H, Zhang D, Wang X, Wu K, Miao D, Fan D. Factor V Leiden and inflammatory bowel disease: a systematic review and meta-analysis. J Gastroenterol 2011; 46: 1158-1166 [PMID: 21805067 DOI: 10.1007/s00535-011-0441-7]
125. Ghosh S, Mackie MJ, McVerry BA, Galloway M, Ellis A, McKay J. Chronic inflammatory bowel disease, deep-venous thrombosis and antithrombin activity. Acta Haematol 1983; 70: 50-53 [PMID: 6191510]
126. Yurekli BP, Aksoy DY, Aybar M, Egesel T, Gurgey A, Hascelik G, Kirazli S, Haznedaroglu IC, Arslan S. The search for a common thrombophilic state during the active state of inflammatory bowel disease. J Clin Gastroenterol 2006; 40: 809-813 [PMID: 17016137 DOI: 10.1097/01. mcg.0000225603.33481.56]
127. van Bodegraven AA, Schoorl M, Linskens RK, Bartels PC, Tuynman HA. Persistent activation of coagulation and fibrinolysis after treatment of active ulcerative colitis. Eur J Gastroenterol Hepatol 2002; 14: 413-418 [PMID: 11943956]
128. Den Heijer M, Lewington S, Clarke R. Homocysteine, MTHFR and risk of venous thrombosis: a meta-analysis of published epidemiological studies. J Thromb Haemost 2005; 3: 292-299 [PMID: 15670035 DOI: 10.1111/j.1538-7836.2005.01141.x]
129. Dawson S, Hamsten A, Wiman B, Henney A, Humphries S. Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasma plasminogen activator inhibitor-1 activity. Arterioscler Thromb 1991; 11: 183-190 [PMID: 1670989]
130. Stegnar M, Uhrin P, Peternel P, Mavri A, Salobir-Pajnic B, Stare J, Binder BR. The 4G/5G sequence polymorphism in the promoter of plasminogen activator inhibitor-1 (PAI-1) gene: relationship to plasma PAI-1 level in venous thromboembolism. Thromb Haemost 1998; 79: 975-979 [PMID: 9609232]
131. Frank RD, Altenwerth B, Brandenburg VM, Nolden-Koch M, Block F. Effect of intravenous high-dose methylprednisolone on coagulation and fibrinolysis markers. Thromb Haemost 2005; 94: 467-468 [PMID: 16116692]
132. Pandit HB, Spillert CR. Effect of methylprednisolone on coagulation. J Natl Med Assoc 1999; 91: 453-456 [PMID: 12656434]
133. El Accaoui RN, Shamseddeen WA, Taher AT. Thalidomide and thrombosis. A meta-analysis. Thromb Haemost 2007; 97: 1031-1036 [PMID: 17549307]
134. Carty E, MacEy M, Rampton DS. Inhibition of platelet activation by 5-aminosalicylic acid in inflammatory bowel disease. Aliment Pharmacol Ther 2000; 14: 1169-1179 [PMID: 10971234]
135. Fägerstam JP, Whiss PA, Ström M, Andersson RG. Expression of platelet P-selectin and detection of soluble P-selectin, NPY and RANTES in patients with inflammatory bowel disease. Inflamm Res 2000; 49: 466-472 [PMID: 11071121]
136. Winther K, Bondesen S, Hansen SH, Hvidberg EF. Lack of effect of 5-aminosalicylic acid on platelet aggregation and fibrinolytic activity in vivo and in vitro. Eur J Clin Pharmacol 1987; 33: 419-422 [PMID: 2965019]
137. Wei JC, Jan MS, Yu CT, Huang YC, Yang CC, Tsou HK, Lee HS, Chou CT, Tsay G, Chou MC. Plasma homocysteine status in patients with ankylosing spondylitis. Clin Rheumatol 2007; 26: 739-742 [PMID: 17024318 DOI: 10.1007/s10067-006-0396-x]
138. Małyszko J, Małyszko JS, Takada A, Myśliwiec M. Effects of immunosuppressive drugs on platelet aggregation in vitro. Ann Transplant 2002; 7: 55-68 [PMID: 12221905]
139. van Ede AE, Laan RF, Blom HJ, Boers GH, Haagsma CJ, Thomas CM, De Boo TM, van de Putte LB. Homocysteine and folate status in methotrexate-treated patients with rheumatoid arthritis. Rheumatology (Oxford) 2002; 41: 658-665 [PMID: 12048292]
140. Bombeli T, Müller M, Straub PW, Haeberli A. Cyclosporineinduced detachment of vascular endothelial cells initiates the intrinsic coagulation system in plasma and whole blood. J Lab Clin Med 1996; 127: 621-634 [PMID: 8648267]
141. van den Dorpel MA, Veld AJ, Levi M, ten Cate JW, Weimar W. Beneficial effects of conversion from cyclosporine to azathioprine on fibrinolysis in renal transplant recipients. Arterioscler Thromb Vasc Biol 1999; 19: 1555-1558 [PMID: 10364089]
142. Al-Shekhlee A, Oghlakian G, Katirji B. A case of cyclosporineinduced dural sinus thrombosis. J Thromb Haemost 2005; 3: 1327-1328 [PMID: 15946232 DOI: 10.1111/j.1538-7836.2005.01387. x]
143. Ingegnoli F, Fantini F, Favalli EG, Soldi A, Griffini S, Galbiati V, Meroni PL, Cugno M. Inflammatory and prothrombotic biomarkers in patients with rheumatoid arthritis: effects of tumor necrosis factor-alpha blockade. J Autoimmun 2008; 31: 175-179 [PMID: 18707846 DOI: 10.1016/j.jaut.2008.07.002]
144. Ingegnoli F, Fantini F, Griffini S, Soldi A, Meroni PL, Cugno M. Anti-tumor necrosis factor alpha therapy normalizes fibrinolysis impairment in patients with active rheumatoid arthritis. Clin Exp Rheumatol 2010; 28: 254-257 [PMID: 20483049]
145. Puli SR, Benage DD. Retinal vein thrombosis after infliximab (Remicade) treatment for Crohn's disease. Am J Gastroenterol 2003; 98: 939-940 [PMID: 12738486 DOI: 10.1111/ j.1572-0241.2003.07368.x]
146. Davies R, Galloway JB, Watson KD, Lunt M, Symmons DP, Hyrich KL. Venous thrombotic events are not increased in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2011; 70: 1831-1834 [PMID: 21784722 DOI: 10.1136/ard.2011.153536]
147. Scarpa M, Pilon F, Pengo V, Romanato G, Ruffolo C, Erroi F, Elisa B, Frego M, Ossi E, Manzato E, Angriman I. Deep venous thrombosis after surgery for inflammatory bowel disease: is standard dose low molecular weight heparin prophylaxis enough? World J Surg 2010; 34: 1629-1636 [PMID: 20177681 DOI: 10.1007/s00268-010-0490-8]
148. Ha C, Magowan S, Accortt NA, Chen J, Stone CD. Risk of arterial thrombotic events in inflammatory bowel disease. Am J Gastroenterol 2009; 104: 1445-1451 [PMID: 19491858 DOI: 10.1038/ajg.2009.81]